Yahoo Finance

UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates

SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of ...
adexchanger

Unity’s AI Ad Platform Is Out Of Beta After A Complete Rebuild

If you’re a mobile platform with access to a vast amount of gaming data, well, then it’s pretty much a foregone conclusion that you’re gonna launch an AI-powered ad platform. AppLovin has Axon and now ...